Actively Recruiting
A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis
Led by InventisBio Co., Ltd · Updated on 2026-04-29
477
Participants Needed
1
Research Sites
98 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a randomized, double-blind, placebo- and active-controlled multicenter clinical trial involving patients with moderate to severe plaque psoriasis. Safety and efficacy assessments will be conducted during the scheduled study visits throughout the trial. After completing the respective treatment, all subjects will undergo a safety follow-up. Both the investigators and subjects will remain blinded throughout the entire treatment period. During the study, subjects are required to provide blood samples for pharmacokinetic (PK) and pharmacodynamic (PD) analyses at the time points specified in the trial protocol.
CONDITIONS
Official Title
A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- The patient voluntarily participates after giving fully informed consent and agrees to follow study procedures
- Aged between 18 and 70 years old, any gender
- Diagnosed with plaque psoriasis suitable for systemic therapy, stable for 6 months or more before consent
- Psoriasis Body Surface Area (BSA) of 10% or more, Physician Global Assessment (PGA) score of 3 or higher, and Psoriasis Area and Severity Index (PASI) score of 12 or higher at screening and Day 1
- Basic normal results in hematology, blood chemistry, and urinalysis tests
- Male and females of childbearing potential agree to use effective contraception or abstain from sexual intercourse from consent until 30 days after last treatment
You will not qualify if you...
- Having any other types of psoriasis including erythrodermic, pustular, guttate, inverse, or drug-induced psoriasis
- Having other skin lesions like eczema that could affect treatment assessment
- History of severe herpes zoster or simplex infection
- History or signs of active or latent tuberculosis
- Unable to understand or unwilling to cooperate due to language barriers
- Pregnant or breastfeeding women
- Any other condition the investigator considers unsuitable for study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Skin Disease Hospital
Shanghai, Shanghai Municipality, China, 200443
Actively Recruiting
Research Team
B
Bingxin Xue
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here